Inhibitory effects of dopamine on high affinity glutamate uptake from rat striatum

Life Sciences ◽  
1982 ◽  
Vol 30 (14) ◽  
pp. 1165-1172 ◽  
Author(s):  
André Nieoullon ◽  
Lydia Kerkerian ◽  
Nicole Dusticier
2004 ◽  
Vol 24 (11) ◽  
pp. 1226-1234 ◽  
Author(s):  
Cecilie Morland ◽  
Karen Astrid Boldingh ◽  
Evy Grini Iversen ◽  
Bjørnar Hassel

The antiepileptic drug valproate (VPA) may be neuroprotective. We treated rats with VPA for 14 days (300 mg/kg twice daily) before intrastriatal injection of 1.5 μmol (1 M) of the succinate dehydrogenase inhibitor malonate. VPA-treated animals developed smaller lesions than control animals: 10 ± 2 mm3 versus 26 ± 8 mm3 (means ± SD; P = 10−4). Injection of NaCl that was equiosmolar with 1 M malonate caused lesions of only 1.2 ± 0.4 mm3 in control animals, whereas physiologic saline produced no lesion. VPA pretreatment reduced the malonate-induced extracellular accumulation of glutamate. This effect paralleled an increase in the striatal level of the glutamate transporter GLT, which augmented high-affinity glutamate uptake by 25%, as determined from the uptake of [3H] glutamate into striatal proteoliposomes. Malonate caused a 76% reduction in striatal adenosine triphosphate (ATP) content, but the glial, ATP-dependent formation of glutamine from radiolabeled glucose or glutamate was intact, indicating that glial ATP production supported uptake of glutamate. Striatal levels of HSP-70 and fos were reduced, and the levels of bcl-2 and phosphorylated extracellular signal-regulated kinase remained unaffected, but histone acetylation was increased by VPA treatment. The results suggest that augmentation of glutamate uptake may contribute importantly to VPA-mediated neuroprotection in striatum.


1987 ◽  
Vol 48 (4) ◽  
pp. 1301-1306 ◽  
Author(s):  
Lydia Kerkerian ◽  
Nicole Dusticier ◽  
André Nieoullon

2000 ◽  
Vol 871 (2) ◽  
pp. 175-180 ◽  
Author(s):  
R.D Azbill ◽  
X Mu ◽  
J.E Springer

Talanta ◽  
2015 ◽  
Vol 135 ◽  
pp. 67-74 ◽  
Author(s):  
O. Soldatkin ◽  
A. Nazarova ◽  
N. Krisanova ◽  
A. Borуsov ◽  
D. Kucherenko ◽  
...  

1996 ◽  
Vol 28 (1-3) ◽  
pp. 127-133 ◽  
Author(s):  
José G. Ortiz ◽  
Olga Claudio ◽  
Glysette Santiago ◽  
Mayra L. Cordero ◽  
Jennifer Nieves

2011 ◽  
Vol 56 (2) ◽  
pp. 1042-1046 ◽  
Author(s):  
Vera Manageiro ◽  
Eugénia Ferreira ◽  
Antony Cougnoux ◽  
Luís Albuquerque ◽  
Manuela Caniça ◽  
...  

ABSTRACTThe clinicalKlebsiella pneumoniaeINSRA6884 strain exhibited nonsusceptibility to all penicillins tested (MICs of 64 to >2,048 μg/ml). The MICs of penicillins were weakly reduced by clavulanate (from 2,048 to 512 μg/ml), and tazobactam restored piperacillin susceptibility. Molecular characterization identified the genesblaGES-7and a new β-lactamase gene,blaSHV-107, which encoded an enzyme that differed from SHV-1 by the amino acid substitutions Leu35Gln and Thr235Ala. The SHV-107-producingEscherichia colistrain exhibited only a β-lactam resistance phenotype with respect to amoxicillin, ticarcillin, and amoxicillin-clavulanate combination. The kinetic parameters of the purified SHV-107 enzyme revealed a high affinity for penicillins. However, catalytic efficiency for these antibiotics was lower for SHV-107 than for SHV-1. No hydrolysis was detected against oxyimino-β-lactams. The 50% inhibitory concentration (IC50) for clavulanic acid was 9-fold higher for SHV-107 than for SHV-1, but the inhibitory effects of tazobactam were unchanged. Molecular dynamics simulation suggested that the Thr235Ala substitution affects the accommodation of clavulanate in the binding site and therefore its inhibitory activity.


2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Zenji Kawakami ◽  
Yuji Omiya ◽  
Kazushige Mizoguchi

The traditional Japanese Kampo medicine yokukansan (YKS) is effective for behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease. As the pharmacological mechanisms, YKS is known to protect astrocytes from thiamine-deficiency (TD)-induced decreased glutamate (Glu) uptake and neuron model cells (PC 12 cells) from Glu-induced death. Yokukansankachimpihange (YKSCH) is an alternative formula to YKS, in which Citrus unshiu peel and Pinellia tuber are added to the YKS components, and is sometimes used to treat BPSD, but its pharmacological properties remain unknown. This study aims to investigate the cellular pharmacological effects of YKS and YKSCH on glutamatergic pathways, compare their efficacy, and determine the differences and similarities in the activities between these formulations. First, we examined the effects of YKS and YKSCH on Glu uptake by cultured astrocytes under TD conditions. We observed significant ameliorative effects of YKS and YKSCH on the TD-induced decrease in Glu uptake, with a 50% effective dose of 8.9 ± 1.8 μg/mL and 45.3 ± 9.2 μg/mL, respectively. Second, using cultured PC12 cells as a model for neurons, we examined the effects of YKS and YKSCH on Glu-induced cell death. We observed that YKS and YKSCH had significant inhibitory effects on Glu-induced cell death, with a 30% effective dose of 51.4 ± 20.8 μg/mL and 49.2 ± 11.0 μg/mL, respectively. Thus, while YKSCH was less effective than YKS in ameliorating the TD-induced decrease in Glu uptake by astrocytes, the two drugs showed similar inhibitory effects on Glu-induced PC12 cell death. These findings are important for understanding the differences and similarities in pharmacological actions between these drugs.


Sign in / Sign up

Export Citation Format

Share Document